Compugen Ltd. Stock
Compugen Ltd. Stock
Compugen Ltd. dominated the market today, gaining €0.20 (8.000%).
With 0 Sell predictions and 1 Buy predictions the community sentiment towards the Compugen Ltd. stock is not clear.
As a result the target price of 5 € shows a very positive potential of 87.97% compared to the current price of 2.66 € for Compugen Ltd..
Pros and Cons of Compugen Ltd. in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Compugen Ltd. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Compugen Ltd. | 8.000% | 9.917% | 45.833% | 128.522% | 102.128% | 383.636% | - |
| Protalix Biotherapeutics Inc. | -4.260% | -6.160% | -1.189% | -30.229% | 19.477% | -15.095% | -64.505% |
| Chromadex Corp | 3.980% | -2.439% | 4.167% | -37.500% | -27.273% | 222.581% | -37.984% |
| Intellia Therapeutics Inc | -14.260% | -8.346% | 4.582% | 62.072% | 49.116% | -64.802% | -82.020% |
Comments
Compugen (CGEN) is now covered by Lake Street Capital. They set a "buy" rating and a $6.00 price target on the stock.
Show more
Ratings data for CGEN provided by MarketBeat
Compugen Ltd. (NASDAQ: CGEN) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $4.00 price target on the stock.
Show more
Ratings data for CGEN provided by MarketBeat
Compugen Ltd. (NASDAQ: CGEN) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.
Show more
Ratings data for CGEN provided by MarketBeat
